Menu
Menu
Tirzepatide works on two metabolic pathways at once. In head-to-head trials it outperformed semaglutide on weight loss. Prescribed with full labs, in-person visits, and monthly follow-up at our Palm Harbor clinic.
Tirzepatide activates two gut hormone receptors instead of one. GLP-1 reduces appetite and slows gastric emptying. GIP (glucose-dependent insulinotropic polypeptide) improves how your body handles fat and glucose, and appears to enhance the weight-loss effect of GLP-1 through a complementary mechanism. The combination produces larger average weight loss than semaglutide in clinical trials, particularly at higher BMI and in patients with significant insulin resistance.
We prescribe a compounded version prepared by a licensed US compounding pharmacy. Same active molecule as Mounjaro (type 2 diabetes) and Zepbound (weight loss), both made by Eli Lilly. Dosing matches the published SURMOUNT trial titration schedule.
If you’re new to GLP-1 therapy entirely, it may be worth reading our compounded semaglutide page first, since that’s usually the starting point. If you’ve already been on semaglutide and plateaued, tirzepatide is often the logical next move.
This is not a telehealth questionnaire. It’s a real medical program.
A full review of your goals, weight history, current medications, and any relevant family history. We decide together whether tirzepatide is the right fit for you specifically.
Baseline A1c, thyroid, kidney, liver, and lipid panel. Body composition at the visit. Your provider writes a dosing and titration plan tailored to your physiology.
Weight, tolerability, and labs rechecked as needed. Dose adjustments are made based on how you’re responding, not a default schedule.
Semaglutide is usually the first-line choice and the more studied of the two. Tirzepatide tends to be the better pick when you have a higher BMI (over 35), significant insulin resistance, a history of PCOS with metabolic features, or haven’t hit your goal on semaglutide alone.
In the SURMOUNT-1 trial (Jastreboff et al., NEJM, 2022), patients on the 15 mg tirzepatide dose lost 22.5% of their body weight over 72 weeks. For context, the best semaglutide result in a comparable trial was 14.9%. SURMOUNT-5, published in 2025, was a head-to-head comparison that confirmed a significant advantage for tirzepatide on weight outcomes. Your provider will help you weigh the decision against cost, tolerance, and your specific goals.
We often start patients on semaglutide, optimize for 4 to 6 months, and switch to tirzepatide only if progress plateaus. That sequencing tends to be kinder on the GI side effects and saves money for patients whose bodies respond well to the single-agonist.
Tirzepatide’s weight-loss evidence comes from the SURMOUNT trial program. SURMOUNT-1 (Jastreboff et al., New England Journal of Medicine, 2022) enrolled 2,539 adults with obesity and followed them for 72 weeks. Mean weight loss was 15.0%, 19.5%, and 20.9% at the 5, 10, and 15 mg doses. The proportion of patients losing 20% or more of their body weight was 30% on the 5 mg dose and 57% on the 15 mg dose.
SURMOUNT-3 looked at patients who first completed a 12-week intensive lifestyle intervention before starting tirzepatide. Those patients achieved 21.1% additional weight loss on top of their initial progress, confirming that medication and lifestyle work synergistically rather than competitively.
SURMOUNT-5 (2025) was the first direct head-to-head against semaglutide. At the highest doses of each, tirzepatide produced meaningfully greater weight loss with a similar safety profile, which cemented it as a reasonable first-line choice for patients who can tolerate the full titration.
Week 1–4. Starting dose is 2.5 mg weekly for the first four weeks. This is the tolerance-building phase. Expect reduced appetite within days and mild GI side effects that improve week over week. We check in at week two.
Week 5–8. Dose advances to 5 mg. Appetite suppression deepens. Most patients begin seeing 2–5 lbs per week of weight loss and start noticing clothes fit differently. Hydration and protein targets become critical.
Week 9–12. Dose moves to 7.5 mg if tolerated. This is typically the dose where patients settle for the first maintenance stretch. We repeat a brief lab panel and assess body composition changes to confirm you’re losing fat, not muscle.
From month four onward, most patients stabilize between 7.5 and 12.5 mg depending on goals and tolerance. A subset reach 15 mg if their target requires it. We revisit dose every month and don’t push harder than your body is ready for.
Monthly program cost depends on your dose and includes the compounded medication, supplies, and your monthly follow-up. Baseline labs are billed separately at wholesale.
For context, Zepbound at pharmacy retail without insurance runs roughly $1,000 or more per month. Our program is designed to be meaningfully more affordable while maintaining clinical safety through real visits and labs. HSA, FSA, and CareCredit are supported. We quote exact numbers at your consultation.
On weight loss alone, head-to-head trials favor tirzepatide at the higher doses. It’s not automatically the right choice for everyone, though. Cost, side-effect profile, and how your body handles dual-receptor therapy all matter. We’ll walk through the trade-offs at your visit.
The active molecule is the same. Mounjaro (for type 2 diabetes) and Zepbound (for weight loss) are Eli Lilly’s brand versions. Our compounded version is prepared by a licensed US 503A compounding pharmacy at a significantly lower cost.
GI side effects lead the list: nausea, reflux, constipation, occasional diarrhea. They’re almost always dose-related and improve with slower titration. Less commonly: gallbladder issues, pancreatitis, and thyroid concerns, which is why we run labs and follow up regularly.
Appetite typically drops in the first two weeks. Visible weight loss usually starts around week four and accelerates as the dose climbs. Expect the biggest changes between month three and month nine.
Yes, and it’s a common path. We review your current labs and dose, then start tirzepatide at a titration that fits where you are. Most patients cross over without a washout period.
Compounded GLP-1/GIP medications are self-pay. For context, most patients find our program cost is meaningfully less than the out-of-pocket cost of Zepbound if insurance denies. HSA and FSA reimbursement is usually eligible.
Like any rapid weight loss, a portion of the loss can be lean mass. We counter this with a high protein intake target (0.8–1.0 g per pound of goal weight), resistance training two to three times per week, and body composition checks so we catch muscle loss before it becomes significant.
Moderate alcohol is fine for most patients. Delayed gastric emptying can intensify the effect of alcohol, so expect to feel it faster and longer. We recommend dialing back initially and seeing how you respond.
Without a taper and a maintenance plan, most patients regain significant weight within six to twelve months. We build the exit plan at the start: a slow taper, a maintenance dose for many, and intentional lifestyle anchors.
Oliver Morris, DO is the prescribing physician at Olympia Aesthetics & Wellness. You see him at every visit. Learn more on the Oliver Morris, DO bio page.
Tirzepatide is a real medication with a specific risk profile. We decline to prescribe when any of the following apply, and we will say so at your consult rather than waste your time.
Individual response varies. This is the pattern most of our patients follow over the first six months.
Lowest dose to assess tolerance. Mild nausea and reduced appetite are common. Hydration and protein-forward meals help early-dose side effects.
First monthly check-in. If you are tolerating 2.5 mg well, we step up to 5 mg. Most patients are 3 to 5% down from starting weight.
Second step. Body composition shifts visible to patient and provider. Labs on schedule check glucose, lipids, and CBC.
Middle of the dose-response curve. HbA1c often improves materially here. We assess whether further titration makes sense.
Many patients settle between 10 and 15 mg. Steady state where side effects are minimal and appetite regulation feels routine. Taper planning begins.
We quote at consultation because the right dose, duration, and bundle depend on your goals and labs. Here is the context.
Pharmacy-compounded tirzepatide prepared by a licensed US compounding pharmacy, shipped to you monthly. In-person consult with Oliver Morris, DO. Monthly follow-up visits with the same provider. Baseline and follow-up labs at scheduled checkpoints. Titration, side-effect management, and nutrition guidance included.
What you are not paying for: membership fees, per-message charges, rotating prescriber pools, or hidden escalations.
Brand-name Zepbound or Mounjaro without insurance runs roughly $1,000 to $1,350 per month at the pharmacy counter. Telehealth compounded tirzepatide programs vary widely and are often sold on a subscription pitch without real medical supervision. Our program is clinically stronger than the latter and competitive with the former.
We quote the full 6 to 12 month program at consultation so you have the total, not a teaser price.
Book an in-person consultation in Palm Harbor. We’ll review your history, run baseline labs, and build a plan the same day.
Enter your email address below to receive our newsletter for events and specials!
Contact information is for the sole use of
Olympia Aesthetics & Wellness and will not be redistributed.
10 am – 6 pm Monday
10 am – 6 pm Tuesday
10 am – 6 pm Wednesday
10 am – 6 pm Thursday
10 am – 6 pm Friday
10 am – 2 pm Saturday
10 am – 2 pm Sunday
Accessibility: Olympia Aesthetics & Wellness is committed to ensuring our website is accessible to all users. If you experience any difficulty, please contact us at (727) 274 – 1972 or [email protected]. Click for more details